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 Emerging rise in microbial drug resistance and the slow-growing characteristic of 
some intracellular pathogens such as MAP (Mycobacterium avium subspecies 
paratuberculosis) strongly urges the need for an effective approach for unconventional 
drug susceptibility testing. We designed a molecular-based PCR method for the 
evaluation of rifabutin (RFB) and rifampicin (RIF) resistance based on probable 
determinant regions within the rpoB gene of MAP, including the 81 bp variable site 
located between nucleotides 1363 and 1443. The minimum inhibitory concentration 
(MIC) for RIF was also determined against 10 MAP isolates in attempt to seek 
correlation with rpoB sequences. We determined that MAP strain 18 had an MIC > 30 
ug/ml and > 5 ug/ml for RIF and RFB respectively, and a significant rpoB mutation 
C1367T, compared to an MIC of < 1.0 ug/ml for both drugs in the wild type MAP. The 
30-fold increase in the MIC was a direct result of the rpoB mutation C1367T, which 
caused an amino acid change Thr456 to Ile456 in the drug’s binding site; the beta 
subunit of RNA polymerase. Our in vitro induced mutation in MAP strain UCF5 resulted 
in the generation of a new resistant strain (UCF5-RIF16r) that possessed T1442C rpoB 
mutation and an MIC > 30 ug/ml and > 10 ug/ml for RIF and RFB respectively. The 
T1442C mutation resulted in a Leu481 to Pro481 amino acid change, consequently 
altering the beta subunit sequence. Sequencing the entire 3.5 kb rpoB in strains 18 and 
UCF5-RIF16r revealed no additional expressed nucleotide mutation.   
 Of the 10 MAP strains analyzed, an additional one strain (UCF4) exhibited a 
slight increase in the MIC against RIF and RFB compared to the wild-type. Nucleotide 
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sequencing of the rpoB gene revealed an A2284C mutation in strain UCF4 that 
occurred further downstream of the expected probable rpoB region and resulted in an 
amino acid alteration Asn762 to His762. The location of this mutation outside the 
binding site and its correlation with the minor increase in MIC suggests a possible 
secondary interaction between the drug and the beta subunit. 
 We have provided three dimensional images through the utilization of PyMol 
Molecular-based Graphics to display a clear comparison of the mutations observed in 
the beta subunit for MAP strains 18, UCF5-RIF16r, and UCF4. We propose that these 
alterations may have caused a less stable interaction between RIF and the beta 
subunit, resulting in the observed increased in MIC. Furthermore, the change in amino 
acid sequence did not affect the viability for our RIF resistant strains.   
 The data clearly illustrates that clinical and in vitro-induced MAP mutants with 
rpoB mutations result in resistance to RIF and RFB. Consequently, unconventional drug 
susceptibility testing such as our molecular approach will be beneficial for evaluation of 
antibiotic effectiveness. This molecular approach may also serve as a model for other 
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1.1. Crohn’s Disease and MAP 
 Crohn’s disease (CD) is an inflammatory bowel disease that detrimentally affects 
the epithelial lining of the digestive tract and includes symptoms such as diarrhea, 
weight loss, abdominal pain, and constipation (12). The disease’s symptoms are similar 
to that of the inflammatory intestinal disease found in cattle, Johne’s disease (JD) (12). 
Currently a strong debate exists between CD’s potential autoimmune cause and it’s 
relation to bacteria, and either concept has yet to be proven. Mycobacterium avium 
subspecies. paratuberculosis, or MAP, is known to be the causative agent of Johne’s 
disease and has previously been implicated in etiological studies of CD (10,11,16). 
Available information regarding MAP’s role in CD has enabled ongoing studies to further 
conclude the relationship between the bacteria and the human disease 
(5,6,9,10,11,13,16,20,21,22,31,32,35,36,38). Evidence has shown that an insertion 
sequence known as IS900 is unique to MAP, and a nested PCR reaction that amplifies 
this region enables the detection of the bacteria in CD samples of blood and tissue, and 
also pasteurized milk (14,31,35). 
1.2. Rifabutin and Rifampicin 
 Rifabutin (RFB) and rifampicin (RIF) are antibiotics that belong to the rifamycin 
drug family and are very similar in chemical structure. The function of these antibiotics 
are to inhibit the growth of bacteria, specifically by binding to the beta subunit of RNA 
polymerase through direct and indirect amino acid interactions, and preventing the 
production of nascent RNA transcripts (7).  
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1.3. rpoB and Rifamycin Resistance 
The rpoB gene in prokaryotes encodes the beta subunit, and it is known that mutations 
within this gene result in a higher level of resistance to the rifamycin antibiotics in 
several bacteria (15,18,25,27,30,33). Moreover, mutations within an 81 base pair region 
in rpoB spanning nucleotides 1276-1356 in Mycobacterium tuberculosis has shown to 
contain the majority of alterations relating to rifamcyin resistance (34). In addition, the 
V176F mutation in the beginning of rpoB has been associated with rifamycin resistance 
in some strains of M. tuberculosis, however this alteration is not as prevalent as the 
former (18,19). 
1.4. Rifabutin and Crohn’s Disease 
 Previous reports have shown that RFB may potentially serve as a therapeutic 
agent for the treatment of CD (17,36). As a result, more attention has been focused on 
the possible use of antibiotics as an alternative remedy. However, a screening method 
for RIF and RFB resistant strains of MAP has yet to be established. Therefore, as CD 
therapy becomes more focused on antibiotics, it is essential that a method for 
susceptibility testing be developed in order to detect and monitor MAP strains for RIF 
and RFB resistance. 
1.5. Fastidious MAP 
 Unlike other prokaryotes, MAP is very fastidious and requires unusual in vitro 
growth conditions, including the addition of Mycobactin J. Additionally, MAP cultured 
from CD samples has shown to lack a cell wall, and this characteristic is a major 
contributing factor to the complexity of the bacteria’s primary isolation process 
(23,31,32). Consequently, conventional drug susceptibility tests involving MAP are not 
reliable and may result in inaccurate measurements. Therefore, the challenges faced 
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when working with this bacterium must be counteracted via alternate approaches that 
could potentially result in the exposition of significant data in order to effectively treat 
MAP infections.  
1.6. Research Objective 
 In this study, we execute a molecular approach based on PCR amplification, 
followed by nucleotide sequencing of regions within the rpoB gene of MAP. We attempt 
to investigate and identify regions of the rpoB gene that exhibit expressed mutation and 
to seek correlation between rpoB mutations in clinical MAP strains with susceptibility to 
RIF and RFB. 
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2. MATERIALS AND METHODS 
 
2.1.  Bacterial Strains 
 Bacterial isolates investigated in this study are listed in Table 1. All clinical strains 
including UCF3, UCF4, UCF5, UCF7, UCF8, M18, M185, and 61a were isolated in our 
laboratory from clinical samples obtained from CD patients (37).  Cow2013, and Cow5 
MAP strains were recently isolated from ground beef samples from two cattle with 
Johne’s disease. In addition, the MAP strains used in our study were previously isolated 
from CD patients and JD cows, and were maintained in culture medium for long-term 
use (Table 1).  
2.2.  Growth Conditions 
 Briefly, tissue samples were homogenized, decontaminated and then inoculated 
into MGIT culture media with supplements including OADC, Mycobactin J and PANTA 
as described previously (37). Prior to inoculation, each BBL MGIT 4 mL tube (Becton 
Dickinson cat #245111) was supplemented with 500 µL MGIT oleic acid-albumin-
dextrose-citrate (OADC) (Becton Dickinson cat # 245116), 100 µL antibiotic mixture 
(200 U Polymyxin B. 287 mcg ampotericin B, 274 mcg nalidixic acid, 20 mcg 
trimethoprim, and 20 mcg azlocillin (PANTA) (Becton Dickinson cat # 245114 ),  8 µL  
Mycobactin J (0.5 mg/mL) (Allied Monitor, USA) and sucrose to a final concentration of 
0.1%. Each MGIT was then inoculated with 500 µL of the homogenized sediment 
suspension using 1 mL sterile syringe with a BD 18G 1½ needle.  After contents were 
mixed well, MGITs were incubated at 37  C in a 5% CO2. The MGIT tubes were 
monitored weekly for visible turbidity or an increase in florescence quenching by 
exposing the tubes to UV light at 365 nm.  
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 All ATCC strains were purchased from ATCC and verified in our laboratory by 
biochemical and molecular testing. All cultures were subcultured in 7H10 agar 
supplemented with OADC and mycobactin J. Plates were incubated at 37oC until visible 
colonies were observed. Colonies from pure culture verified by Ziel-Neelson acid fast 
stain and IS900-based PCR for MAP were used to incoculate BACTEC 7H9 broth 
culture supplemented with 500 uL OADC and 2.4 uM Mycobactin J. Growth index (G.I.) 
was read weekly until optimum growth of desired G.I. was observed. The fresh culture 
was then used for drug susceptibility testing and for molecular studies. 
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Table 1  List of microorganisms used in the study. 
Microorganism Strain Source 
MAP 43544 ATCC 
MAP UCF3, Clinical Isolate CD, Ileal  
MAP UCF4, Clinical Isolate CD, Ileal 
MAP UCF5, Clinical Isolate CD, Ileocolonic  
MAP UCF7, Clinical Isolate CD, Ileocolonic  
MAP UCF8, Clinical Isolate CD, Ileal  
MAP 18, Clinical Isolate CD, Ileal 
MAP 185, Clinical Isolate CD, mesenteric lymphnode 
MAP 61a, Clinical Isolate CD, Ileal 
MAP Cow2013 JD, ground beef 
MAP Cow5 JD, ground beef 
M. avium subspecies. 
avium 
25291 ATCC 
M. tuberculosis Ra25177 ATCC 




2.3. Minimum Inhibitory Concentration (MIC) 
 MIC for RIF and RFB were determined against microorganisms listed in Table 1 
as follows.  Starting cultures with a G.I. in the range of 500-600 were determined to be 
best for inoculation. The inoculum size for each Bactec bottle used in the drug 
susceptibility study was approximately 1.0 x 10^5 CFUs. Serial dilutions of RIF 
concentration ranging from 0.0 to 4 ug/ml were evaluated against all microoganisms. 
MAP strains resistant to RIF > 1.0 ug/ml were further tested against RIF concentrations 
of 10, 20 and 30 ug/mL for MIC measurement. These MAP strains were also evaluated 
against RFB at concentrations ranging from 0.0 to 10 ug/mL, excluding UCF4. MAP wild 
type was included as a control in every batch of analysis. Experiments were repeated 
for confirmations. Microganisms other than MAP were also evaluated for RIF 
concentrations ranging from 0.0 to 10.0 ug/mL. The percentage of RIF or RFB inhibition 
was used to determine the level of susceptibility for each concentration of antibiotic as 
follows: % Inhibition = 1 minus (G.I of Bactec culturewithout drug  minus G.I of Bactec 
culture with drug G.I.)/ G.I of Bactec culturewithout drug). The MIC was also determined for 
each bacterial sample, and was defined as the minimum concentration of antibiotic that 
induced 90% inhibition of growth. 
2.4. DNA Extraction 
 Extraction of genomic DNA from mycobacterial isolates was performed for 
verification of the presence of the IS900 gene and for analysis of rpoB gene sequence. 
For extraction of genomic DNA from Mycobacterium paratuberculosis, the boiling 
method with the use of Phase-Lock Gel tubes, PLG (Eppendorf 0032005-101) gave excellent 
results. The procedures for this method are summarized as follows: Before sampling, 
 8 
incubated MGIT tubes were thoroughly vortexed.   Sample of 500μL was aseptically 
taken from each MGIT cultures, using a sterile disposable 1 mL syringe with a long 
sterile needle BD 18G 11/2, and placed into a 1.5 mL sterile eppendorf tubes.  Tubes 
were centrifuged at 12,000 rpm for 10 minutes at 4  C.   Supernatants were removed; 
using micropipeter with aerosol barrier tips, into an autoclavable container containing 30 
mL bleach.  Pellets, containing mycobacterial cells, were re-suspended in 100 μL sterile 
TE buffer (10 mM Tris and 1 mM EDTA, pH 8.0 HCl).  The tubes were incubated in a 
dry heat bath at 100  C for 30 minutes, thereafter placed on ice for 15 minutes. 
 Immediately prior to use, Phase-Lock Gel tubes, PLG, 2-mL light (Eppendorf cat 
# 0032 005 101) were pelleted in a microcentrifuge at 12,000 rpm for 20 seconds at 4  
C..  The tubes containing DNA were centrifuged at 12,000 rpm for 10 minutes at 4  C.  
Supernatants were transferred into the Phase Lock Gel tubes using a micro 
micropipette with sterile aerosol-barrier tips.  Then, 200 µL of phenol / chloroform / iso 
amayl alcohol (Acros Organics, cat # 327115000) was added to each PLG tube, 
thoroughly mixed with the aqueous sample to form a transiently homogeneous 
suspension..  The PLG tubes were then centrifuged at 12,000 rpm for 5 minutes at 4  C.  
The gel of PLG formed a barrier between the aqueous and organic phases.   The 
aqueous upper phase containing DNA was carefully transferred to a fresh 1.5 mL 
eppendorf sterile tube using sterile aerosol-barrier tips.  To precipitate extracted DNA, 
400 µL of 100% ethanol cooled to -20  C was added to each tube, mixed well, then 
tubes were incubated at –20 C overnight.  Tubes were centrifuged at 14,000 rpm for 20 
minutes at 4  C.  Supernatants were removed and DNA pellets were washed with 400 
μL of 80% ethanol.  Tubes were re-centrifuged at 14,000 rpm for 20 minutes at 4  C.   
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Supernatants were removed and DNA pellets were dried in a speed vacuum for 10 
minute at room temperature.  Finally, 50 µL of sterile millipore water was added to each 
dried DNA pellet and allowed to re-dissolve at 4 C overnight. 
2.5. Nested PCR 
 Nested PCR for IS900 amplification was performed using the primers p90/91 and 
AV1/AV2 (Table 2) as described previously (31). The amplification product size was 
determined on 2% agarose gel. Appropriate negative controls for PCR consisted of 
sterile TE buffer or sterile water in place of the DNA template were used in parallel with 
each round of PCR preparation. Positive MAP DNA from strain ATCC 43015 was 
prepared independently and added to PCR tubes at a different facility using separate 
supplies. 
2.6. rpoB PCR 
 Unlike the nested IS900-based PCR assay, only one round of PCR assays were 
developed for amplification of two different regions of the rpoB gene. Therefore, one 
PCR reaction contained the UCF1/UCF2 primers for an amplification of 448 bp where 
as the second PCR reaction contained the Knight1/Knight 2 primers for an amplification 
of 587 bp. For polymerase chain reaction, the following reagents were added in 
respective order in a 500-μL sterile PCR tube: 12.30 µL of Millipore sterile, filtered and 
autoclaved water, 5.00 µL of 10x Platinum Taq polymerase buffer with MgCl2 (Invitrogen), 
6.00 µL 25mM Magnesium solution  (Invitrogen), 8.50 µL of 3M Betaine (ICN 101003), 1.00 µL 
of 10 mM each PCR Nucleotide Mix dNTP(Fisher Bp2565-2), 1.00 µL of either forward primer 
UCF1 (5’TCGATGTCGCTGTCTTTCTC) or Knight1 (5’ACCACTTCGGCAACCGCCGG) 
at a concentration of 0.125 μg/μL, 1.00 µL of either reverse primer UCF2 (5’ 
GCTCGGTGATCTGCTCGTTG) or Knight2 (5’ACTCGACCTCGCCCGCCTTG) at a 
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concentration of 0.125 μg/μL, 0.20 µL of Platinum Taq DNA Polymerase (Invitrogen), and 
15.00 µL of extracted DNA (Template) 0.3 – 3.0 ng/µL, making a total of 50.00 µL per 
0.5 µL PCR tube. Table 2 lists the nucleotide sequence for all primers used in this 
study. 
 Additional PCR was performed for MAP strains UCF4, M18, and UCF5-RIF16r 
using the same protocol as previously described. Table 4 displays information regarding 
additional rpoB primers and the corresponding regions that each primer set amplifies.  
2.7. PCR Purification 
 Each rpoB PCR product was purified from agarose using the PurelinkTM Quick 
Gel Extraction Kit following the procedure as described by the manufacturer 
(InvitrogenTM). Purified DNA was then quantitated and subjected to nucleotide 
sequencing.  
2.8. Nucleotide Sequencing 
 Sequencing was performed using the GenomeLabTM DTCS – Quick Start Kit 
following the procedure as described by the manufacturer (Beckman Coulter®). Each 
sequencing reaction contained the following reagents their corresponding range of 
volumes: 0 – 9.5 ul dionized H2O, 0.5 – 10 ul DNA (PCR) template, 2.0 ul primer 
(forward or reverse), and 8 ul DTCS Quick Start Master Mix totaling 20 ul. The thermal 
cycling protocol consisted of 30 cycles using the following times and temperatures: 
96oC for 20 seconds, 50oC for 20 seconds, and 60oC for 4 minutes. Sequenced DNA 
was then precipitated in individual tubes using the following protocol: a) Prepare a 
labeled, sterile 0.5 ml microfuge tube for each sample, b) Prepare fresh Stop 
Solution/Glycogen mixture as follows (per sequencing reaction): 2 ul of 3M Sodium 
Acetate (pH5.2), 2 uL of 100 mM Na2-EDTA (pH 8.0) and 1 ul of 20 mg/mL of glycogen. 
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To each of the labeled tubes, add 5 uL of the Stop Solution/Glycogen mixture, c) 
Transfer the sequencing reaction to the appropriately labeled 0.5 mL microfuge tube 
and mix thoroughly, d) Add 60 uL cold 95% (v/v) ethanol/dH2O from -20
oC freezer and 
mix thoroughly. Immediately centrifuge at 14,000 rpm at 4oC for 15 minutes. Carefully 
remove the supernatant with a micropipette (the pellet should be visible), e) Rinse the 
pellet 2 times with 200 ul 70% (v/v) ethanol/dH2O from -20
oC freezer. For each rinse, 
centrifuge immediately at 14,000 rpm at 4oC for a minimum of 2 minutes. After 
centrifugation carefully remove all of the supernatant with a micropipette, f) Vacuum dry 
for 10 minutes (or until dry), g) Resuspend the sample in 40 ul of the Sample Loading 
Solution (provided with kit). Following the sequencing reaction, capillary electrophoresis 
was performed using the appropriate nucleotide primers for both strands of the PCR 
product at the Biomolecular Science Center DNA Sequencing Core facility at the 
University of Central Florida.   
2.9. BLAST 
 BLAST and alignment sequence analyses was performed using 
www.pubmed.gov. Briefly, sequences were obtained from the ftp://name@10.169.1.31 
database available through the Burnett College of Biomedical Sciences at the University 
of Central Florida. Sequences were used to align and BLAST against the wildtype K-10 
MAP strain available on pubmed.gov. Both forward and reverse reactions were 
analyzed for mismatches and sequences were reported for each MAP isolate 
accordingly. 
2.10. In-Vitro Mutant 
 A RIF resistant MAP mutant (UCF5-RIF16r) was generated through the induction 
of an rpoB mutation. This was performed by exposing a wild-type MAP strain UCF5 to 
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increasing concentrations of RIF ranging from 1 to 16 ug/ml. Initially, MAP strain UCF5 
was inoculated into a BACTEC bottle containing 1 ug/ml of RIF. Following incubation, 
surviving MAP cells were subcultured into a new BACTEC bottle with double RIF 
concentration. The process was repeated several times until a new MAP strain (UCF5-
RIF16r) was generated that was able to survive in the presence of 16 ug/ml of RIF. This 
new resistant strain was then tested for MIC against RIF and RFB and investigated for 
possible rpoB mutations as described earlier. 
2.11. PyMOL Images 
 Protein database (pdb) file 1Ynn was obtained from the RCSB Protein Data Bank  
www.rcsb.org/pdb/home/home.do website, and docking images were provided through 
the use of DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application 






3.1. IS900 Verification 
 Genomic DNA from all bacterial isolates was subjected to IS900-based PCR in 
order to confirm the identity of the MAP strains listed in Table 1. This procedure 
involved two rounds of PCR, using p90/91 primers in the first round to amplify a 400 bp 
sequence (Fig 1).  The use of AV1/AV2 in the second round of PCR amplified a 308 bp 
sequence and provided exceptional sensitivity and enhanced specificity for the 
confirmation of MAP. All 10 MAP isolates were confirmed for the presence of IS900 (Fig 
2, lanes 1-11). As expected, M. avium subspecies avium, M. smegmatis and M. 
tuberculosis displayed negative results for the presence of the IS900 (Fig 2, lanes 12-
14). Succeeding the IS900 PCR analysis, genomic DNA from each identified MAP strain 




Figure 1  IS900-based PCR for detection of MAP using P90/P91 primers. 
 
This first round of the nested PCR using P90/P91 primers generated a 400 bp sequence displayed 
on 2% agarose gel. Lanes 1-16 correspond to the following: 1, MAP strain 43544 (positive control); 
2, UCF3; 3, UCF4; 4, UCF5; 5, UCF7; 6, UCF8; 7, M18; 8, MAP185; 9, Cow2013; 10, Cow5; 11, 61a; 
12, M. avium; 13, M. tuberculosis; 14, M. smegmatis, 15, TE buffer; 16, negative control.





   
 
 
Figure 2  IS900-based PCR for detection of MAP using AV1/AV2 primers. 
 
This second round of the nested PCR using AV1/AV2 primers generated a 308 bp on 2% agarose 
gel. Lanes 1-8 correspond to MAP strains isolated from human tissue samples (1, MAP strain 
43544 (control); 2, UCF3; 3, UCF4; 4, UCF5; 5, UCF7; 6, UCF8; 7, MAP18; and 8, MAP185; 
respectively. Lanes  9 and 10 correspond MAP strains derived from cattle tissue (strains Cow2013 
and Cow5, respectively). Lane 11 corresponds to a new MAP strain 61a from human tissue. Lanes 
12-14 correspond to M. avium subspecies avium,, M. tuberculosis and M. smegmatis, respectively. 
Lanes 15 and 16 correspond to negative control for DNA extraction and PCR, respectively. A low 
mass DNA molecular weight marker was used and bp are indicated on the left of the diagram. 
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Table 2  PCR primers used in this study. 
Primer Type 
and Name 





    P90 
    P91 
 
    AV1 
    AV2 
 
rpoB 
    UCF1 
    UCF2 
     
    Knight1 








































*Numbers represent nucleotide positions within the rpoB gene of MAP. 
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3.2. rpoB PCR 
 Amplification of rpoB sequences enabled the possibility for amplicon purification, 
sequencing, and subsequently BLAST analysis. The use of primers UCF1/UCF2 and 
Knight1/Knight2 enabled the amplification of two regions of the rpoB gene of MAP. 
These regions overlapped similar sequences in the rpoB gene of M. tuberculosis 
previously associated with rifamycin resistance. Moreover, PCR with Knight1/Knight2 
primers amplified a sequence that harbored the 81 bp variable site 1363-1443, a highly 
probable determinant region for rifamycin resistance in closely related bacteria.  Figure 
3 shows the PCR results of these two regions of the rpoB gene from each of five MAP 
strain representatives.  
   
 
Figure 3  Partial rpoB amplicons produced by PCR. 
 
These five samples including the positive control were chosen to represent the results of rpoB 
PCR for all MAP strains in this study. Lanes 1-6 represent PCR using primers UCF1/UCF2, and 
each lane corresponds to a 448 bp amplicon and is associated with the following MAP strains: 1, 
43544 (positive control); 2, UCF4; 3, UCF5; 4, MAP18; 5, MAP185; 6, negative control. Lanes 7-12 
represent PCR using primers Knight1/Knight2, and each lane corresponds to a 587 base pair 
amplicon and is associated with the following MAP strains: 7, 43544 (positive control); 8, UCF4; 9, 
UCF5; 10, MAP18; 11, MAP185; 12, negative control. A low mass DNA marker was used and the 
numbers located on both sides of the image indicate base pair lengths for two different bands 




3.3. rpoB Sequencing 
       Nucleotide sequencing of regions ampliied by primers UCF1/UCF2 and 
Knight1/Knight2 for all MAP strains was performed using a High Fidelity Platinum  Taq 
polymerase. The process was repeated and the sequence was verified with both 
forward and reverse primer reactions to exclude any possible errors in the data. 
Therefore, sequence data was reported as completely accurate upon the confirmation 
of error-free reactions. We investigated the regions amplified by primers UCF1/UCF2 
and Knight1/Knight2 in 10 MAP strains, which resulted in the detection of either identical 
(wild-type) or non-identical sequences (Table 3). MAP strains consisting of the latter 
were further detected for silent mutations with no effect on amino acid expression, or 
mutations that differentially expressed the amino acid sequence of the beta subunit. The 
location of each changed amino acid was then identified and determined to lie within the 
81 bp region contained in the sequence amplified by primers Knight1/Knight2 (Fig 4).  
 Of the 10 MAP clinical isolates, 9 (90%) consisted of no rpoB mutation in the two 
regions investigated, however, 1 (10%) MAP strain, M18, possessed two rpoB 
mutations, and these included C1367T and T1375C (Fig 4). The C1367T mutation 
resulted in a significant amino acid change from Thr456 to Ile456 in the beta subunit of 
RNA polymerase (Fig 4, Table 3). This amino acid change was considered indicative of 
RIF and RFB resistance, which later was verified through susceptibility tests. The 
T1375C mutation had no affect on the beta subunit, and was therefore characterized as 
silent (Fig 4, Table 3). MAP isolates were then classified based on sequence 
information from both regions (Fig 5). Isolates that contained no mutations were termed 
wild-type and were classified as identical compared to the K-10 sequence rpoB 
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sequence. Consequently, isolates that possessed mutations were classified as non-
identical. The effect of rpoB mutations in these regions on RIF and RFB susceptibility 





Figure 4  Sequence alignment of the 81 base pair region in the rpoB gene of MAP. 
 
The region dispayed overlaps the 81 bp rifamycin resistant determinant region within M. tuberculosis. For MAP, this sequence is 
harbored in the region amplified by primers Knight1/Knight2. Indicated base pairs and amino acids range from 1363 to 1443, and 456 to 
481 respectively. All RFB and RIF resistant mutations were observed within this region. Amino acid-changing rpoB mutations are 
indicated for MAP18 and UCF5-RIF16r, while other rpoB mutations were considered silent. Dots correspond to homologous bases and 




Figure 5  Characterization of MAP isolates. 
 
According to rpoB sequence information regarding regions amplified by primers UCF1/UCF2 and Knight1/Knight2, one of the ten MAP 




UCF3, UCF4, UCF5, UCF7












Table 3  rpoB and susceptibility data for all microorganisms. 






Inhib. at 1 


























UCF3 < 1.0 n/a 94  2.83 WT None 
MAP 
 
UCF4 < 2.5 n/a 79  7.07 A2284C N762H 
MAP 
 
UCF5 < 1.0 n/a 92.5  0.71 WT None 
MAP 
 
UCF7 < 1.0 n/a 88  5,66 WT None 
MAP 
 
UCF8 < 1.0 n/a 90  1.41 WT None 







Cow2013 < 1.0 n/a 95  1.41 WT None 
MAP 
 
Cow5 < 1.0 n/a 96.5  0.71 WT None 
MAP 
 





ATCC25291 < 1.0 n/a 90  1.41 n/a n/a 
M. tuberculosise 
 
ATCC25177 < 1.0 n/a 92  1.41 n/a n/a 
M. smegmatise 
 









a. Limited investigation involving MAP18, and UCF5-RIF16r. 
b. Values are expressed as means  the standard deviation (SD). 
c. Wildtype (WT) indicates identical investigated rpoB sequence compared to MAP K-10 strain. 
d. The amino acid change is indicated with single letter amino acid codes and the corresponding codon 
number. 




  Correlation between rpoB sequence analysis and inhibitory growth rates for RIF 
was assessed for all 10 MAP strains. MAP strains were initially tested against 1 ug/ml of  
RIF, the MIC for our control (Fig 6). MAP strains were then subjected to MIC tests 
against the same drug (Fig 7). All strains clearly indicated a susceptible characteristic 
by ceasing growth at 1ug/ml of RIF, the MIC of our wild-type control, except UCF4, 
M18, and UCF5-RIF16r (UCF5-RIF16r explained in later sections). More specifically, 9 
MAP strains including ATCC43544 (control), UCF3-5, UCF7-8, 61a, Cow2013, Cow5, 
and two non-MAP controls including M. tuberculosis and M. avium subspecies avium 
had an MIC < 1.0 ug/mL for RIF (Fig 7, Table 3). After analyzing our susceptibility 
results (Fig 6, Fig 7), MAP strains displaying suspicious characteristics of RIF 
resistance were then subjected to a susceptibility test against RFB (Table 3). Only MAP 
strain M18 displayed growth of up to 5 ug/ml of RFB, indicating partial resistance to this 
drug as well. The MIC for RIF of the remaining MAP strains 18, UCF4, and M. 
smegmatis was determined as > 30, < 2.5, > 9 ug/ml respectively (Table 3). Despite the 
lack of rpoB mutations, M. smegmatis is commonly characterized as a naturally RIF 
resistant bacteria. Table 3 summarizes rpoB mutations and susceptibility test values for 





















































































Figure 6  Percent inhibition at 1 ug/ml of RIF for each bacterial sample. 
 
The y-axis represents inhibition of growth expressed as a percentage. The x-axis represents all 
bacterial isolates tested. The growth rate of MAP18, UCF4, MAP185, M. smegmatis and UCF5-


























































































Figure 7  Minimum Inhibitory Concentration (MIC) for each bacterial sample. 
 
The Y-axis represents the concentration of RIF expressed in ug/ml, while the X-axis represents all 
bacterial samples used for MIC testing. MAP18 and UCF5-RIF16r displayed similar MICs due to 
significant rpoB mutations. The MIC for MAP185 and UCF4 were slightly above that of the control, 
but not comparable to the resistant MAP strains. M. smegmatis displayed RIF resistance due to 






 In order to determine the possibility of inducing in vitro RIF resistance in MAP, 
our wild-type MAP strain UCF5 was cultured in two-fold increases of RIF concentration 
initially beginning at a concentration of 1ug/ml. Over an extended time period, strain 
UCF5 was eventually increased to 16ug/ml, a concentration in which the strain had 
developed an adaptive resistance. After determining a high level of growth at this 
concentration, we then termed the newly resistant MAP strain UCF5-RIF16r. The 
adapted strain and was then maintained in cultures  >16.0 ug/mL RIF thereafter.  
 Genomic DNA was extracted and followed by IS900-nested PCR and rpoB-
based PCR analysis to investigate the possibility of a newly developed rpoB mutation. 
After strain UCF5-RIF16r was confirmed for the presence of IS900, and both regions of 
the rpoB gene were analyzed, we detected a single nucleotide rpoB mutation T1442C in 
the 81 bp variable region amplified by primers Knight1/Knight2, which caused a 
differentially expressed amino acid from Leu481 to Pro481 in the beta subunit of RNA 
polymerase (Fig 4, Table 3). The effect of this induced mutation on susceptibility to RIF 
was then investigated through susceptibility tests involving RIF as well as RFB. MAP 
strain UCF5-RIF16r was tested against RIF up to greater than 30 ug/mL and up to 
greater than 10 ug/mL for RFB. We determined that the MIC for UCF5-RIF16r against 
RIF and RFB was > 30 ug/mL and > 10 ug/mL, respectively (Fig 7, Table 3).  
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3.6. Blood Mixture 
 To show the potential for sequence analysis in the rpoB gene of MAP clinical 
isolates in correspondence with RIF and RFB resistance, we contaminated Human 
peripheral blood mononuclear cells (PBMNC) with 1.0 x 10^3 CFU of MAP strain 18. 
Prokaryotic genomic DNA was then extracted from the blood mixture, followed by 
IS900-PCR and rpoB-based PCR analysis. As expected, our developed protocol 
detected MAP in the blood sample and successfully amplified both regions of the rpoB 
gene of MAP (data not shown). The nucleotide sequence was then analyzed for the 
possible prediction of susceptibility to RIF or RFB. 
3.7. Taq Alignment 
 Specific amino acids are commonly known to alter upon resistance to RIF in M. 
tuberculosis, a close relative of MAP. Moreover, theThermus aquaticus (Taq) beta 
subunit model has previously been provided and aligned with M. tuberculosis. In order 
to relate our current information with that previously shown, we aligned the variable 
region in MAP with Thermus aquaticus and M. tuberculosis for comparison purposes 
(Fig 8). Within the alignment (Fig 8) we provided a color coding scheme obtained from 
Campbell et al. 2001 corresponding to known amino acids positions and interaction data 
relevant to the RIF-Taq beta subunit complex. As displayed, colored dots indicate 
positions of amino acids relative to the bound RIF molecule. Amino acid alterations that 
have occurred in M. tuberculosis are also noted below their corresponding positions, 
and percentages are indicated for amino acid alterations that occur at high frequency 
upon RIF resistance in M. tuberculosis. Amino acid changes that occurred in MAP strain 
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18 and induced MAP strain UCF5-RIF16r within this region are indicated in bold at 
positionsThr456 and Leu481.  
 According to our alignment analysis of the MAP beta subunit relevant to the 
region shown in Figure 8, Arg388 in Thermus  aquaticus overlaps that of Thr456 in 
MAP, and this amino is not considered to make significant interactions with bound RIF 
according to Campbell et. al 2001 (Fig 8). Moreover, Leu481 in MAP overlaps Leu413 in 
Taq, and this amino acid is considered to make significant Vanderwaals interactions 
with RIF in its bound state, possibly contributing to a more significant interaction with the 
drug. The significance of our alignment is that we may determine how the amino acid 
changes observed in MAP relate to commonly known residue changes that may occur 
in M. tuberculosis, and to predict positions and the significance of each amino acid 






Figure 8  Sequence alignment of MAP with Thermus aquaticus and Mycobacterium tuberculosis. 
 
Color Key: 
Grey shaded areas indicate identical residues compared to T.a. 
Yellow dots correspond to amino acids that interact directly with RIF. 
Green dots correspond to distal amino acids relevant to RIF. 
Purple dots indicate amino acids that alter at a high frequency upon RIF resistance, with the percentage change indicated. 
T.a., Thermus aquaticus 
M.p. Mycobacterium avium spp. paratuberculosis 
M.t. Mycobacterium tuberculosis 
Bold amino acid change indicates mutations that occurred in M.p.  
 
Figure 8 is modified from Figure 1 of Campbell et al 2001. 
*Mutation that occurred only for M.p. 
 
 
T.a. 385 F F S R S Q L S Q F K D E T N P L S S L R H K R R I S A L G P G G 417
M.p. 453 F F G T S Q L S Q F M D Q N N P L S G L T H K R R L S A L G P G G 485
M.t. 424 F F G T S Q L S Q F M D Q N N P L S G L T H K R R L S A L G P G G 456
D I* H P T L L I V H M L Y L P
R K V Y D W
P E C R T C
G G L Q Q
A N P E Y
36%9% 41%
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3.8. 3-D perspective 
 In order to obtain a photographic representation of the amino acid changes that 
occurred in MAP strains M18 and UCF5-RIF16r, we utilized the only available model 
available through PyMol Molecular-based Graphic program (DeLano 2005) for the 
display of RIF complexed with the beta subunit. The images shown are of the Taq 
model for the purpose of substituting for MAP. In order to view all PyMol images, we 
obtained protein database files from the RSBC PDB databank available through the 
www.rcsb.org/pdb/home/home.do  website. The specific pdb file that was utilized for 
visualization of Taq RIF complex model was 1YNN. Through this file, we were able to 
provide Figures 9, 10, 11, and 12.  
3.8.1  MAP strain 18 3-D model 
 The first displayed RIF complex model substitutes for MAP strain M18 (Fig 9). To 
describe, the Arg388 in Thermus aquaticus overlaps Thr456 in the beta subunit of MAP 
strain 18 (Fig 8). In Thermus aquaticus, this amino acid residue interacts with a nearby 
E384 within an alpha helix (Fig 9) which may contribute to the surrounding structure of 
the RIF pocket. As mentioned, we detected a Thr456 to Ile456 in MAP strain 18. We 
have shown this overlapping alteration from Arg388 to Ile388 in Thermus aquaticus for 
substitute for this change in MAP, and propose that this change may possibly reflect the 
observed increase in MIC due to a modification of the nearby structural atmosphere of 
the bound RIF (Fig 10). For example, if the surrounding lock structure for a key is 
altered, then the key will most likely not fit. More specifically, the Arg388 to Ile388 
alteration may destabilize the alpha helix structure close to the RIF molecule, and 
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possibly affect the surrounding structure or pocket where RIF binds, resulting in a less 
stable RIF interaction.  
 
 
DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005) 
 
Figure 9  Thermus aquaticus RIF complex model for MAP wildtype.  
 
For Thermus aquaticus, R388 (Thr456 in MAP) is located within an alpha helix nearby the RIF 
antibiotic in its bound state. R388 is indicated by the white arrow. Surrounding beta subunit is 
shown as green and RIF antibiotic is shown as tan. Oxygen elements are shown as red and 
nitrogen elements are shown as blue. 
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005) 
 
Figure 10  Thermus aquaticus RIF complex for resistant MAP strain 18.  
 
The specific alteration that is shown here is Arg388 to Ile388. This alteration represents that 
observed for MAP strain 18, Thr456 to Ile456. This alteration may possibly destabilize RIF 
interaction by altering a nearby alpha helical structure. The alteration is shown as gray, 
surrounding beta subunit is shown as green and RIF antibiotic is shown as tan. Oxygen elements 
are shown as red and nitrogen elements are shown as blue. 
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3.8.2 UCF5-RIF16r 3-D model 
 The second Taq RIF complex display substitutes for our wild-type MAP strain 
UCF5, as well as the induced MAP strain UCF5-RIF16r. To describe, Leu413 in 
Thermus aquaticus, which overlaps Leu481 in MAP (UCF5), interacts with Leu391 in 
close proximity to RIF in its bound state, contributes to Vanderwaal interactions with 
RIF, and may also contribute to the interactive stability between RIF and the beta 
subunit (Fig 11). As mentioned before, we have detected that a Leu481 to Pro481 
alteration occurred in MAP strain UCF5-RIF16r upon resistance to RIF, and this 
alteration may also destabilize RIF interaction. An illustration of the Leu413 to Pro413 
alteration in Taq is provided (Fig 12). To support our statement explaining the 
interaction between Leu481 and the RIF antibiotic, we have included a Taq RIF 
complex diagram provided by Campbell et. al. 2001 which shows Leu413 clearly 
interacting in close proximity to bound RIF (Fig 13).  
3.8.3 Proposition 
 In both cases involving MAP strain M18 and UCF5-RIF16r, we propose that the 
amino acid alteration within this variable region causes a high level of resistance to RIF 
in MAP directly or indirectly. In addition, the changes observed do not affect the viability 
of for both strains. The Thermus aquaticus RNA polymerase RIF-complex provides an 
excellent model for illustrative purposes, and here we employ this available model to 
substitute for a visual representation of the overlapping amino acids observed in our 





DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005) 
 
Figure 11  Thermus aquaticus RIF complex for wildtype MAP strain UCF5.  
 
Both Leu391 and Leu413 make Vanderwaals interactions with RIF in its bound state. The white 
arrow indicates Leu413. Surrounding beta subunit is shown as green and RIF antibiotic is shown 
as tan. Oxygen elements are shown as red and nitrogen elements are shown as blue.
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005) 
 
Figure 12  Thermus aquaticus RIF complex for resistant MAP strain UCF-RIF16r.  
 
The Leu413 to Pro413 alteraction may contribute an interruption in Vanderwaals interactions 
between Leu413 and the RIF antibiotic, consequently destabilizing RIF interaction. The alteration 
is shown as gray, surrounding beta subunit is shown as green and RIF antibiotic is shown as tan. 
Oxygen elements are shown as red and nitrogen elements are shown as blue.
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Campbell et al 2001 
 
 
Figure 13  Interactions with RIF and RNA polymerase. 
 
The Lue413 residue in T.a. overlaps that of Leu481 in MAP. This diagram clearly shows Leu413 in 
Taq interacting with bound RIF through Vanderwaals inteactions, as also previously stated by 




3.9. Additional Sequencing 
 We attempted to sequence the entire 3.5 kb rpoB gene in order to determine the 
source of the variable increase in MIC for RIF against MAP strains UCF4, and to detect 
any other possible rpoB mutations leading to amino acid alterations in strains M18 and 
UCF5-RIF16r. Initially, we designed additional primers (Table 4) for PCR amplification 
of additional sequences outside of that amplified by primers UCF1/UCF2 and 
Knight1/Knight2. Our PCR results are shown in  Figures 14-18, which represent the rest 
of the rpoB gene in each MAP strain mentioned. After successful PCR amplification of 
these regions, nucleotide sequencing was performed.   
 Blast analysis against the rpoB gene of MAP strain K-10 (wild-type) revealed a 
significant rpoB mutation further downstream of the region amplified by Knight1/Knight2 
primers in MAP strain UCF4. Specifically, an A2284C mutation occurred within the 
region amplified by primers Ex1a/Ex2a. This mutation resulted in an Asn762 to His762 
amino acid change, leading to a possible explanation for the observed higher MIC for 
RIF compared to our wildtype control strain 43544. Moreoever, no other significant 
mutations were observed in MAP strains 18 and UCF5-RIF16r. The data clearly 
indicates that a single rpoB mutation may have considerable effects on RIF 
susceptibility in MAP, and that the region amplified by primers Knight1/Knight2 is highly 




Table 4  Additional rpoB PCR primers. 
Primer Type 
and Name 





  Efox1 
  Fox1r 
 
  Fox1f 
  DBR 
 
  Ex1a 
  Ex2a 
 
  Ex3 
  Ex4 
 
  Ex5 

















































Figure 14  rpoB PCR results using Efox1/Fox1r primers.  
 
Each lane corresponds to the following MAP strains: 1, 43544 (positive control); 2, UCF4; 3, M18; 





Figure 15  rpoB PCR results using Fox1/DBR primers.  
 
Each lane corresponds to the following MAP strains: 7, 43544 (positive control); 8, UCF4; 9, M18; 




Figure 16  rpoB PCR results using Ex1a/Ex2a primers.  
 
Each lane corresponds to the following MAP strains: 1, 43544 (positive control); 2, UCF4; 3, M18; 




Figure 17  rpoB PCR results using Ex3/Ex4 primers. 
 
Each lane corresponds to the following MAP strains: 1, 43544 (positive control); 2, UCF4; 3, M18; 




Figure 18  rpoB PCR results using Ex5/Hrox1 primers. 
 
Each lane corresponds to the following MAP strains: 7, 43544 (positive control); 8, UCF4; 9, M18; 
10, UCF5-RIF16r; 11, M185;, 12, negative control. 
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3.10. UCF4 3-D model 
 After obtaining the entire rpoB sequence for MAP strain UCF4, which revealed a 
A2284C mutation causing a Asn762 to His762 amino acid change, we provided a third 
Taq RIF complex display to illustrate the observed alteration in the beta subunit. To 
explain, Glu692 in Taq overlaps Asn762 in MAP, and this amino acid lies within an 
alpha helical structure somewhat distant from RIF in its bound state (Fig 19). The 
Glu692 to His692 change shown in Figure 20 represents the Asn762 to His762 
alteration in MAP strain UCF4. Reverting back to our lock and key example, we propose 
that the surrounding RIF pocket is again modified, however our RIF susceptibility tests 
for strain UCF4 indicate that the modification within the beta subunit was not as 
detrimental as compared to MAP strains M18 and UCF5-RIF16r. 
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005) 
 
Figure 19  Thermus aquaticus RIF complex for wild-type MAP.   
 
The Glu692 is indicated by the white arrow, and contributes to the slpha helical structure shown. 
Glu692 in this Taq model substitutes for Asn762 in wild-type MAP. Surrounding beta subunit is 
shown as green and RIF antibiotic is shown as tan. Oxygen elements are shown as red and 
nitrogen elements are shown as blue. 
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005) 
 
Figure 20  Thermus aquaticus RIF complex for MAP strain UCF4.  
 
The specific alteration that is shown here is Glu692 to His692 in Taq, which substitutes for the 
Asn762 to His762 change seen in MAP strain UCF4. This change may possibly explain the variable 
increase in MIC against RIF for strain UCF4. The alteration is shown as gray, surrounding beta 
subunit is shown as green and RIF antibiotic is shown as tan. Oxygen elements are shown as red 




3.11. Entire rpoB Sequence 
 After collective analysis of our rpoB PCR and sequencing results, we were able 
to display the entire rpoB gene sequence for MAP strains K-10, (wild-type control 
sequence), M18, UCF5-RIF16r, and UCF4,. The ability to display this information was a 
direct consequence of our successful PCR and sequencing reactions involving the 
primers described in Table 2 and Table 4. Figures 21, 22, 23, and 24, allow a clear 
observation of the significant nucleotide positions C1367, T1442 and A2284 relative to 
the rest of the rpoB gene. The 81 bp region is bolded for all complete gene sequence 
figures 21,22,23, and 24 and the corresponding nucleotide mutations are indicated as 
blue bold for silent, and red bold for amino acid-changing. Notice that the rpoB mutation 
for MAP strain UCF4 is outside of the 81 bp variable region, and as mentioned before, 
this mutation led to a less significant change in the MIC against RIF. This indicates that 
the significant region for detection of RIF resistance in MAP is located within the 81 bp 
bolded region shown. 
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag 
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc 
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac 
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag 
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc 
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag 
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg 
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc 
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc 
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc 
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag 
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac 
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg 
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc 
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc 
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag 
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac 
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac 
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc 
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg 
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag 
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg 
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcaccag ccagttgtcc 
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg 
1441 ctgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg 
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc 
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc 
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac 
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc 
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac 
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc 
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg 
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac 
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac 
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg 
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag 
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag 
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc 
2281 tccaaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc 
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc 
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc 
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag 
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg 
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac 
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc 
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag 
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg 
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg 
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc 
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc 
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc 
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg 
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag 
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag 
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc 
3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc 
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3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc 
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc 
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg 
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa 
 
Figure 21  Entire rpoB gene sequence for MAP strain K-10, wild-type control 
sequence (Li et al 2005). 
 
The 81 bp variable region is bolded and located between nucleotides 1363 and 1443. 
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag 
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc 
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac 
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag 
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc 
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag 
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg 
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc 
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc 
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc 
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag 
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac 
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg 
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc 
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc 
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag 
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac 
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac 
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc 
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg 
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag 
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg 
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcactag ccagttgtcc 
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg 
1441 ctgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg 
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc 
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc 
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac 
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc 
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac 
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc 
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg 
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac 
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac 
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg 
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag 
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag 
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc 
2281 tccaaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc 
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc 
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc 
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag 
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg 
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac 
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc 
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag 
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg 
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg 
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc 
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc 
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc 
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg 
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag 
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag 
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc 
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3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc 
3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc 
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc 
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg 
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa 
 
Figure 22  Entire rpoB gene sequence for MAP strain M18. 
 
The C1367T and T1375C mutations are indicated bold with their corresponding colors and 
increased font. Red bold circled positions correspond to mutations that caused an amino acid 
alteration, and blue bold correspond to silent mutations. 
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag 
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc 
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac 
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag 
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc 
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag 
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg 
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc 
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc 
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc 
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag 
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac 
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg 
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc 
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc 
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag 
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac 
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac 
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc 
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg 
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag 
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg 
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcaccag ccagttgtcc 
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg 
1441 cCgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg 
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc 
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc 
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac 
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc 
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac 
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc 
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg 
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac 
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac 
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg 
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag 
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag 
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc 
2281 tccaaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc 
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc 
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc 
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag 
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg 
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac 
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc 
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag 
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg 
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg 
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc 
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc 
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc 
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg 
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag 
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag 
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc 
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3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc 
3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc 
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc 
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg 
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa 
 
Figure 23  Entire rpoB sequence for induced MAP strain UCF5-RIF16r.  
 
The T1442C mutation caused an amino acid change in this strain. Red bold circled positions 




1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag 
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc 
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac 
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag 
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc 
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag 
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg 
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc 
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc 
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc 
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag 
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac 
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg 
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc 
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc 
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag 
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac 
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac 
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc 
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg 
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag 
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg 
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcaccag ccagttgtcc 
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg 
1441 ctgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg 
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc 
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc 
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac 
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc 
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac 
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc 
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg 
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac 
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac 
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg 
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag 
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag 
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc 
2281 tccCaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc 
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc 
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc 
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag 
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg 
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac 
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc 
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag 
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg 
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg 
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc 
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc 
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc 
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg 
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag 
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag 
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc 
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3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc 
3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc 
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc 
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg 
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa 
 
Figure 24  Entire rpoB sequence for MAP strain UCF4.  
 
Note the A2284C mutation and its position relative further downstream of the 81 bp variable 
region. Red bold circled positions correspond to mutations that caused an amino acid alteration, 




 The purpose of our experiment was to characterize MAP’s potential for 
developing RFB and RIF resistance, associate RFB and RIF resistance with mutations 
in the rpoB gene of MAP, and provide an effective protocol for detecting resistant 
mutations in MAP strains linked to CD. Bacteria such as M. avium spp. avium, E. coli, 
H. pylori, S. aureus and M. kansasii have laid the foundation for RFB and RIF 
resistance through mutations in the rpoB gene (15,19,25,30,33). Moreover, various 
strains of the closely related M. tuberculosis have set a fine trend for rifamycin 
resistance, as seen through rpoB mutations (1,2,3,4,8,19,20,27,29,41). Our goal was to 
discover this trend in MAP, and develop an effective method for analyzing RFB and RIF 
resistance in the bacterium through rpoB-based PCR analysis.  
4.2.  Rationale 
 The overall concept of our research was to develop a method for detecting RIF 
and RFB resistance in MAP strains to effectively treat CD as well as MAP related 
infections. In order to thoroughly approach our goal, we established necessary steps to 
evaluate the level of susceptibility to RIF and RFB in MAP. Therefore, the most effective 
approach was to perform the following: Identify all MAP isolates through the commonly 
known IS900 nested PCR reaction. Then investigate rpoB sequences in regions 
commonly known to develop mutations upon RIF resistance. These regions were 
harbored in those amplified by UCF1/UCF2 and Knight1/Knight2 primers. These regions 
overlap similar sequences in the rpoB gene of M. tuberculosis that have displayed 
mutations upon rifamycin resistance, including the 81 bp region 1276-1356 within 
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cluster I, as well as a region further upstream in the beginning of rpoB (18,19,34). 
Consequently, our determinant regions of interest in the rpoB gene of MAP were 
selected based on the available information for closely related bacteria. 
Our expected results were to discover no mutations in these regions for susceptible 
MAP strains. However, upon our recognition of the slight increase in MIC of MAP strain 
UCF4, we performed additional sequencing to address our unexpected finding and to 
determine any additional mutations in our highly resistant MAP strains M18 and UCF5-
RIF16r. We then discovered a possible rationale for the increase in MIC in strain UCF4 
through the detection of a mutation further downstream of our expected regions, 
suggesting that alternative regions of the beta subunit may influence the interactive 
stability between RIF and its target.  
4.3.  An alternative approach 
 There are many limitations regarding assay performance with MAP, and these 
include the bacterium’s slow growing nature. To cope with this limitation, we show an 
alternative approach that may be applied to this bacterium for the analysis RFB and RIF 
resistance. Provided by our example of using human PBMNC-infected with MAP, we 
suggest that significant data relevant to genetic resistance to antibiotics may be 
obtained without the inconvenient time constraint involved with conventional inhibitory 
tests. For example, analysis of the rpoB gene of MAP will indicate the likelihood of 
susceptibility to RFB and RIF. This information was validated by our in vitro 
susceptibility tests for using 10 MAP isolates from various sources, which display low 
MICs for MAP isolates without significant rpoB mutations, and higher MICs for MAP 
isolates with significant rpoB mutations.  
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4.4.  Molecular analysis 
 Of our 10 MAP isolates, 2 (20%) showed a suspicious indication for RIF 
resistance, and these were MAP strains 18 and UCF4. MAP strain 18 consisted of a 
significant rpoB mutation, C1367T, which induced an amino acid change in the beta 
subunit, Thr456 to Ile 456, consequently causing the observed increase in MIC. On the 
other hand, MAP strain UCF4 contained an rpoB mutation further downstream of the 81 
bp variable site, and this mutation caused an amino acid alteration Asn762 to His762, 
resulting in only a slight increase in MIC compared to strain M18. This suggests that the 
81 bp region was of upmost significance for the evaluation of highly RIF and RFB 
resistant MAP strains. Moreover, the difference in the level of susceptibility suggests 
that this characteristic may vary depending on the location of the amino acid alteration.  
4.5.  Induced resistance 
 Our induced in vitro resistant MAP strain, UCF5-RIF16r, was indicative of RIF 
resistance after it’s observed growth in the presence of 16 ug/ml, and rpoB mutation 
T1442C. The new mutation caused a differential amino acid expression Leu481 to 
Pro481, and its significance was observed through the association of a higher MIC 
against RFB and RIF compared to the control. This data, combined with our analysis of 
MAP strain 18, showed the potential for MAP to evolve resistance to RFB and RIF in 
vivo and in vitro.   
4.6.  Blood mixture 
 A separate experiment in which we applied our rpoB-based protocol on human 
blood mixed with a specific quantity of MAP.  This was accomplished through 
contaminating normal human blood with 1 x 10^3 CFU’s of MAP strain 18, and 
extracting bacterial DNA directly from the blood mixture. As a result, a sufficient amount 
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of bacterial DNA was obtained for successful amplification of our regions of interest 
within rpoB (data not shown). The purpose of this approach was to demonstrate the 
effectiveness of our protocol on CD patient blood. 
4.7.  Final Comments 
 In conclusion, through the application of our protocol on CD patient samples, we 
may assist in the determination of RFB and RIF susceptible MAP strains for the 
treatment of CD. Upon the observed in vitro generation of a RFB and RIF resistant MAP 
strain (UCF5-RIF16r), it is likely that this trend may occur in vivo, as supported with data 
from MAP strain 18. Furthermore, as RFB is applied more towards the treatment of CD, 
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